Uni-Bio Science Group Ltd. (0690) AI Stock Analysis

• Market Cap: HK$643.37M
• Dividend Yield: 2.56%
• Average Volume (3M): 25.35M
• Price to Earnings (P/E): 8.0
• Beta (1Y): -0.12
• Revenue Growth: 14.08%
• EPS Growth: 21.62%
• Country: HK
• Employees: 487
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 0.01
• Shares Outstanding: 5,971,228,000
• 10 Day Avg. Volume: 10,511,199
• 30 Day Avg. Volume: 25,354,613
• PEG Ratio: -0.04
• Price to Book (P/B): 2.35
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 22.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 73 Outperform
• Price Target: ―

Uni-Bio Science Group Ltd. demonstrates strong financial performance with robust revenue growth and profitability, supported by a solid balance sheet. However, the absence of operating cash flows necessitates careful liquidity management. Technical indicators are moderately positive, suggesting a potential upward trend. The stock's attractive valuation, indicated by a low P/E ratio, provides further investment appeal despite the lack of dividends.

Uni-Bio Science Group Ltd. Business Overview & Revenue Model

Company Description

Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, an EGF eye drop for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Bokangtai, a mitiglinide tablet for the treatment of Type 2 diabetes, as well as Boshutai, an oral anti-diabetic drug targeting patients with pre-diabetes condition. It is also developing prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; and rhPTH 1-34 (Uni-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agonist, a non-insulin treatment candidate for the treatment of Type 2 diabetes. The company was founded in 2001 and is headquartered in Sha Tin, Hong Kong.

How the Company Makes Money

Uni-Bio Science Group Ltd. generates revenue through the sale and distribution of its pharmaceutical products and biotechnology solutions. The company's revenue model is centered around its core therapeutic areas, including diabetes, ophthalmology, and dermatology. By developing proprietary drugs and entering into strategic partnerships with other pharmaceutical companies, Uni-Bio Science Group Ltd. enhances its market reach and product offerings. Additionally, the company benefits from licensing agreements and collaborations that allow it to leverage external expertise and resources, further contributing to its earnings. The focus on innovation and addressing unmet medical needs enables the company to maintain a competitive edge in the biopharmaceutical industry.

Uni-Bio Science Group Ltd. Financial Statement Overview

Summary

Uni-Bio Science Group Ltd. exhibits strong revenue growth and improving profitability, reflected in its income statement. The balance sheet is sound with low leverage and strong equity, supporting financial stability. However, the cash flow statement raises potential concerns due to the absence of operating cash flows in 2024. Overall, the company is on a positive growth trajectory, though attention to cash flow management is advised.

Income Statement

The income statement shows a strong performance with consistent revenue growth, marked at 14.1% from 2023 to 2024, and improving profitability. The gross profit margin is high at 83.4% for 2024, indicating effective cost management. The net profit margin improved to 15.0% in 2024, reflecting increased efficiency. Both EBIT and EBITDA margins have shown positive trends, at 17.4% and 20.5% respectively, up from previous years.

Balance Sheet

The balance sheet reflects a stable financial position with a strong equity base. The debt-to-equity ratio remains low at 0.35, indicating low leverage. The equity ratio is robust at 62.9%, suggesting a healthy capital structure. Return on equity improved to 25.4% in 2024, showcasing efficient use of equity capital. Overall, the balance sheet demonstrates financial stability with potential for growth.

Cash Flow

Cash flow from operations is non-existent in 2024, which may raise concerns about cash generation capabilities. Historically, free cash flow showed positive growth, but recent results are unavailable. The absence of operating and free cash flow data in 2024 suggests a need for cautious monitoring of liquidity and cash management strategies.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	552.98M	484.72M	440.32M	353.40M	208.78M
Gross Profit	461.07M	392.82M	334.88M	277.01M	181.09M
EBITDA	113.56M	93.56M	61.21M	1.31M	-49.95M
Net Income	82.77M	70.88M	38.51M	-19.59M	-71.32M
Balance Sheet
Total Assets	517.55M	409.99M	292.47M	267.59M	252.72M
Cash, Cash Equivalents and Short-Term Investments	183.90M	129.24M	98.22M	83.61M	61.04M
Total Debt	115.19M	56.30M	22.67M	5.60M	3.14M
Total Liabilities	191.91M	152.82M	97.72M	93.29M	63.31M
Stockholders Equity	325.64M	257.17M	194.75M	174.31M	189.41M
Cash Flow
Free Cash Flow	0.00	39.11M	20.23M	3.61M	-28.45M
Operating Cash Flow	68.87M	98.85M	48.66M	12.04M	-15.47M
Investing Cash Flow	0.00	-76.14M	-27.03M	42.12M	-24.65M
Financing Cash Flow	0.00	24.51M	2.58M	478.00K	-5.41M

Uni-Bio Science Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.11
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0690, the sentiment is Positive. The current price of 0.11 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.09, and above the 200-day MA of 0.07, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 57.10 is Neutral, neither overbought nor oversold. The STOCH value of 71.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0690.

Uni-Bio Science Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0690	73 Outperform	HK$643.37M	8.00	28.40%	2.56%	14.08%	21.62%
2126	59 Neutral	HK$1.17B	―	-41.34%	―	-10.78%	24.88%
2257	54 Neutral	HK$611.02M	―	-266.90%	―	―	31.23%
Sector *	52 Neutral	$7.52B	0.25	-63.76%	2.30%	16.15%	0.89%
1244	52 Neutral	HK$1.30B	―	-21.22%	―	-31.34%	67.95%
6628	51 Neutral	HK$700.65M	―	-32.59%	―	-79.65%	37.50%
9939	36 Underperform	HK$796.92M	―	-41.20%	―	―	85.23%

Uni-Bio Science Group Ltd. Corporate Events

Uni-Bio Science Group Ltd. Announces Annual General Meeting and Key Resolutions

Uni-Bio Science Group Ltd. has announced its upcoming annual general meeting scheduled for May 26, 2025, where key agenda items include the adoption of financial statements, re-election of directors, and re-appointment of auditors. The meeting will also consider resolutions to authorize the board to issue new shares, which could impact the company’s capital structure and shareholder value.

Uni-Bio Science Group Ltd. Forms Nomination Committee to Strengthen Board Governance

Uni-Bio Science Group Ltd. has established a Nomination Committee to oversee the composition and effectiveness of its Board of Directors. The committee, which includes a majority of Independent Non-Executive Directors, is tasked with reviewing board structure, identifying potential board members, assessing independence, and making recommendations on director appointments and succession planning. This initiative aims to enhance corporate governance and align the board’s composition with the company’s strategic goals.

Uni-Bio Science Group Achieves Record Profit and Expands Product Line

Uni-Bio Science Group Ltd. reported a 14.1% increase in revenue to approximately HK$553.0 million and a 16.8% rise in profit to HK$82.8 million for the year ended December 31, 2024, marking a historic high. The company launched Bogutai®, which exceeded sales expectations, and recommended a final dividend payment. The company also introduced a new medical aesthetics product and advanced its ophthalmology drug pipeline, reinforcing its commitment to innovation and cost control.

Uni-Bio Science Group Ltd. Declares Final Dividend for 2024

Uni-Bio Science Group Ltd. has announced a final cash dividend of HKD 0.00277 per share for the financial year ending December 31, 2024. The dividend will be payable on June 13, 2025, following shareholder approval on May 26, 2025. This announcement reflects the company’s ongoing commitment to returning value to its shareholders and may influence investor perceptions positively.

Uni-Bio Science Group Announces New Board Composition

Uni-Bio Science Group Limited, a company incorporated in the Cayman Islands, has announced the composition of its board of directors as of March 27, 2025. The board includes executive, non-executive, and independent non-executive directors, with Mr. Kingsley Leung serving as Chairman. This announcement outlines the roles and functions of the directors, as well as their membership in various board committees, reflecting the company’s governance structure and leadership strategy.

Uni-Bio Science Group Schedules Board Meeting for Financial Results and Dividend Discussion

Uni-Bio Science Group Ltd. has announced a board meeting scheduled for March 27, 2025, to approve the company’s financial results for the year ending December 31, 2024, and to discuss the potential recommendation of a final dividend. This meeting is crucial for stakeholders as it will provide insights into the company’s financial health and strategic decisions, potentially impacting its market positioning and investor confidence.

Uni-Bio Science Group Announces Registrar Change

Uni-Bio Science Group Limited, a company listed on the Hong Kong Stock Exchange, has announced a change in its branch share registrar and transfer office in Hong Kong. Effective from March 17, 2025, Tricor Investor Services Limited will take over these responsibilities. This transition requires applications for the registration of transfer of shares to be lodged with Tricor Investor Services Limited from the specified date. This move indicates a strategic shift in the company’s administrative operations, potentially affecting stakeholders involved in share registration and transfers.